Detroit R&D, Inc. was founded in 1997 by Dr. Hyesook Kim as a company dedicated to building a relationship of trust with the research community, by providing the highest quality products through leading-edge technology. Detroit R&D specializes in environmental health-, hypertension- and cancer-related research, including biologically active eicosanoids such as EETs and DHETs, prostaglandin H synthases (PGHSs, also called cyclooxygenases, COXs), cytochromes P450 (CYPs), glutathione S-transferases (GSTs), oxidative stress, DNA damage, Xenopus microarray and wound healing.

Detroit R&D is a young company but already has established a track record of success:

• We have funding for five active or completed National Institutes of Health (NIH) SBIR Phase I and II projects (two of these are active Phase II), including hypertension diagnosis, PGHS-dependent DNA damage and microarray projects.

• Detroit R&D is an awardee of the first round Michigan Life Sciences Corridor Fund as a partner company for elucidation of the mechanisms of a eukaryotic drug pump.

• Detroit R&D holds 3 allowed and 8 pending patents.

In summary, Detroit R&D has the talent, insight and drive to grow substantially. We welcome collaborational and/or licensing inquiries.